Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA

Vertex's (VRTX) Trikafta NDA Gets Priority Review by FDA

Source: 
Yahoo/Zacks.com
snippet: 

Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination therapy, Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor).